Year All2024202320222021202020192018201720162014201320112010 June 13, 2022 Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022 June 2, 2022 Rhythm Pharmaceuticals Announces New Employment Inducement Grants May 5, 2022 Rhythm Pharmaceuticals Announces New Employment Inducement Grants May 4, 2022 Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference May 3, 2022 Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update May 2, 2022 Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting April 26, 2022 Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 April 8, 2022 Rhythm Pharmaceuticals Announces New Employment Inducement Grants April 6, 2022 Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity March 1, 2022 Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference
June 13, 2022 Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022
May 2, 2022 Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
April 26, 2022 Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 6, 2022 Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
